Raloxifene similarly affects the skeletal system of male and ovariectomized female rats.
Journal Title: Pharmacological Reports - Year 2007, Vol 59, Issue 3
Abstract
Raloxifene, a selective estrogen receptor modulator, is used for prevention and treatment of osteoporosis in postmenopausal women. Raloxifene use in male subjects is increasingly considered and a few clinical studies of its effect on bone turnover have already been performed. The aim of the present study was to investigate the effects of raloxifene on the skeletal system of healthy mature male rats. The experiments were performed on mature male Wistar rats, treated daily with raloxifene hydrochloride at a dose of 5 mg/kg po for 4 weeks. Bone mass, mineral content, macrometric and histomorphometric parameters, as well as mechanical properties were examined. For comparison, we also studied the effects of raloxifene on the skeletal system of mature ovariectomized female rats. Raloxifene administration to male rats caused statistically significant increases in the bone mass/body mass ratio, bone mineral content/body mass ratio and bone mineral content/bone mass ratio in comparison with those of the control rats. Bone mechanical properties and most of histomorphometric parameters remained unchanged. Also in ovariectomized female rats, raloxifene administration caused statistically significant increases in the bone mass/body mass ratio, bone mineral content/body mass ratio and bone mineral content/bone mass ratio in comparison with the results obtained in the ovariectomized control rats, to the level of sham-operated control rats. Moreover, raloxifene counteracted the development of changes in histomorphometric parameters caused by ovariectomy in female rats, but did not significantly affect bone mechanical properties. In conclusion, the changes induced by raloxifene in the skeletal system of male rats were similar to those induced by the drug in ovariectomized female rats.
Authors and Affiliations
Joanna Folwarczna, Leszek Śliwiński, Urszula Cegieła, Maria Pytlik, Ilona Kaczmarczyk-Sedlak, Barbara Nowińska, Waldemar Janiec, Henryk Trzeciak
Keywords
Related Articles
- EP ID EP128913
- DOI -
- Views 101
- Downloads 0
Trimetazidine increases [3H]glucose uptake in rat brain.
Trimetazidine, a clinically effective antianginal agent with no negative inotropic or vascular properties, acts by optimizing cardiac energy metabolism through inhibition of free fatty acid oxidation, shifting substrate...
Sir John Robert Vane (1927-2004).
Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats.
We studied the effect of an eight-week treatment with telmisartan (5 mg kg(-1)day(-1)) on cardiovascular complications that are associated with type 2 diabetes in a neonatal rat model. Type 2 diabetes was induced by the...
Frequency of common CYP3A5 gene variants in healthy Polish newborn infants.
Cytochrome P450 monooxygenases catalyze the metabolism of approximately 40-60% of widely used drugs with a A6986G CYP3A5 polymorphism determining expresser (A6986, *1) and reduced- expresser (*3) variants with modified d...
C3435T polymorphism of the ABCB1 gene: impact on genetic susceptibility to peptic ulcers.
The functional single nucleotide polymorphism (SNP) C3435T in exon 26 of the ABCB1 gene encoding the xenobiotic transporter P-glycoprotein (P-gp) may influence susceptibility to several diseases, as well as the clinical...